1 rich Libsyn https://www.libsyn.com 90 600 Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan &amp; HFpEF &amp; Functional MR; Digitoxin &amp; Heart Failure In this week’s View, Dr. Eagle examines&amp;nbsp;recent research into&amp;nbsp;maintaining&amp;nbsp;weight loss with tirzepatide.&amp;nbsp;He then&amp;nbsp;offers insights into the new dyslipidemia&amp;nbsp;guidelines,&amp;nbsp;including addressing reproductive and hormone risk factors in&amp;nbsp;cardiovascular risk assessment.&amp;nbsp;Next, Dr. Eagle&amp;nbsp;looks&amp;nbsp;at the use of&amp;nbsp;sacubitril/valsartan&amp;nbsp;to improve exercise tolerance&amp;nbsp;in patients with&amp;nbsp;heart failure with reduced ejection fraction (HFpEF)&amp;nbsp;and functional&amp;nbsp;mitral regurgitation (MR).&amp;nbsp;Finally, Dr. Eagle&amp;nbsp;summarizes&amp;nbsp;a new study on the use of&amp;nbsp;digitoxin and&amp;nbsp;digoxin&amp;nbsp;in patients with heart failure.&amp;nbsp; Subscribe to Eagle’s Eye View  &amp;nbsp; Eagle's Eye View: Your Weekly CV Update From ACC.org http://www.acc.org <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/41439805/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/202353725